IOVS Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLeod, D. S.
Right arrow Articles by Lutty, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLeod, D. S.
Right arrow Articles by Lutty, G. A.
(Investigative Ophthalmology and Visual Science. 2002;43:474-482.)
© 2002 by The Association for Research in Vision and Ophthalmology, Inc.

Localization of VEGF Receptor-2 (KDR/Flk-1) and Effects of Blocking It in Oxygen-Induced Retinopathy

D. Scott McLeod1, Makoto Taomoto1, Jingtai Cao1, Zhenping Zhu2, Larry Witte2 and Gerard A. Lutty1

1 From the Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; and the 2 Department of Molecular and Cell Biology, ImClone Systems Inc., New York, New York.

PURPOSE. Vascular endothelial cell growth factor (VEGF) has been implicated in vascular development and in proliferative retinopathies. The goal of this study was to examine the immunohistochemical localization and relative levels of VEGF receptor-2 (KDR) in canine retina during postnatal vasculogenesis and during angiogenesis in oxygen-induced retinopathy (OIR) and to investigate the effects of neutralizing KDR on these processes.

METHODS. Eyes from normal dogs ranging from 1 to 22 days of age and age-matched oxygen-treated animals were snap frozen for immunohistochemical analysis with antibodies against human KDR. To examine the effects of blocking KDR, 6-day-old air-reared control and oxygen-treated animals were surgically implanted with slow release polymer pellets containing control IgG or anti-KDR. Material eluted from pellets was assessed using a binding assay (measures binding to soluble KDR) to determine the kinetics of anti-KDR release and endothelial cell proliferation to measure bioactivity. Animals were killed at 22 days of age and tissues examined with adenosine diphosphatase (ADPase) histochemical staining of blood vessels.

RESULTS. KDR immunoreactivity was only weakly associated with developing retinal vessels and was not observed in angioblasts throughout normal postnatal development. Immunoreactivity was very strong in reforming retinal vessels and intravitreal neovascularization in oxygen-treated animals. Anti-KDR had no effect on vessel morphology or growth in air-reared control animals. In oxygen-treated animals, anti-KDR significantly inhibited revascularization of the retina (P = 0.005) and formation of intravitreal neovascularization compared with control IgG pellet eyes (P < 0.04).

CONCLUSIONS. KDR/Flk-1 was only weakly associated with normal developing primary retinal vessels but was strongly expressed by proliferating endothelial cells in reforming retinal vessels and intravitreal neovascularization after hyperoxic insult. Anti-KDR antibody delivered by slow-release pellets had no effect on normal vasculogenesis, but it inhibited the formation of intravitreal neovascularization and retinal vessel development in OIR. The study suggests that blocking KDR may be beneficial for treating pathologic angiogenesis in adult tissue.




This article has been cited by other articles:


Home page
Br. J. Ophthalmol.Home page
C Pieh, H Agostini, C Buschbeck, M Kruger, J Schulte-Monting, U Zirrgiebel, J Drevs, and W A Lagreze
VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity
Br. J. Ophthalmol., May 1, 2008; 92(5): 689 - 693.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. D. Monte, M. Cammalleri, D. Martini, G. Casini, and P. Bagnoli
Antiangiogenic Role of Somatostatin Receptor 2 in a Model of Hypoxia-Induced Neovascularization in the Retina: Results from Transgenic Mice
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3480 - 3489.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Satofuka, A. Ichihara, N. Nagai, T. Koto, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, H. Itoh, et al.
Role of Nonproteolytically Activated Prorenin in Pathologic, but Not Physiologic, Retinal Neovascularization
Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 422 - 429.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
E. Banin, M. I. Dorrell, E. Aguilar, M. R. Ritter, C. M. Aderman, A. C. H. Smith, J. Friedlander, and M. Friedlander
T2-TrpRS Inhibits Preretinal Neovascularization and Enhances Physiological Vascular Regrowth in OIR as Assessed by a New Method of Quantification
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2125 - 2134.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. H. Yoo, H.-J. Hyun, J.-Y. Koh, and Y. H. Yoon
Riluzole Inhibits VEGF-Induced Endothelial Cell Proliferation In Vitro and Hyperoxia-Induced Abnormal Vessel Formation In Vivo
Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4780 - 4787.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
G. Bergers and S. Song
The role of pericytes in blood-vessel formation and maintenance
Neuro-oncol, October 1, 2005; 7(4): 452 - 464.
[Abstract] [PDF]


Home page
IOVSHome page
N. Nagai, K. Noda, T. Urano, Y. Kubota, H. Shinoda, T. Koto, K. Shinoda, M. Inoue, T. Shiomi, E. Ikeda, et al.
Selective Suppression of Pathologic, but Not Physiologic, Retinal Neovascularization by Blocking the Angiotensin II Type 1 Receptor
Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1078 - 1084.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
R. Z. Renno, Y. Terada, M. J. Haddadin, N. A. Michaud, E. S. Gragoudas, and J. W. Miller
Selective Photodynamic Therapy by Targeted Verteporfin Delivery to Experimental Choroidal Neovascularization Mediated by a Homing Peptide to Vascular Endothelial Growth Factor Receptor-2
Arch Ophthalmol, July 1, 2004; 122(7): 1002 - 1011.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. Chan-Ling, D. S. McLeod, S. Hughes, L. Baxter, Y. Chu, T. Hasegawa, and G. A. Lutty
Astrocyte-Endothelial Cell Relationships during Human Retinal Vascular Development
Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 2020 - 2032.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Association for Research in Vision and Ophthalmology